Background/aims Retinopathy of prematurity (ROP) is a sight-threatening disease, requiring efficient screening and treatment. The present study aims to describe various aspects on treatment for ROP in Sweden.
Methods Data on treatment for ROP in infants born in 2008–2012 were extracted from Swedish national register for retinopathy of prematurity, a web-based national register.
Results During 2008–2012, 3488 infants with a gestational age (GA) at birth of <31 weeks had been screened for ROP in Sweden. Altogether, 30.3% (1057/3488) of the infants developed ROP and 5.2% (181/3488) were treated. Type 1 ROP was found in at least one eye in 83.2% (149/179) of the treated infants. One third of the eyes (32.2% right, 29.9% left eyes) were treated more than once. Laser was the only treatment in 90% of the eyes. Mean number of laser spots at first laser session was 1177 and 1386 in right and left eyes, respectively. Number of laser spots correlated negatively with GA at birth (p=0.01). There was no change in frequency of treatment or number of laser spots during the 5-year period. Anti-vascular endothelial growth factor injections were performed in 28 eyes, encircling band was used in five eyes and vitrectomies were performed in seven eyes. Twenty-six retinal surgeons performed 9.4 (range 1–37) treatment sessions in the 181 infants.
Conclusions The present study reveals similar incidences of ROP and frequencies of treatment during the 5-year study period. Many surgeons were involved in treatment of a rather limited number of infants. The results call for national discussions on organisation of ROP treatment.
- Child health (paediatrics)
Statistics from Altmetric.com
Contributors All authors substantially contributed to design, acquisition and interpretation of the work, revised it critically, approved the final version and agreed to be accountable for all aspects of the work.
Funding The study was supported by the Nordströmer Foundation, the Foundation for the Visually Impaired in former Malmöhus county and the Stig and Ragna Gorthon Foundation.
Competing interests None declared.
Ethics approval Faculty of Medicine, Uppsala University, Sweden.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Raw data could be made available on request and discussion with the authors.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.